Selection and characterization of Toxoplasma gondii mutants resistant to artemisinin

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 1128-1131

  Berens, Randolph L ^a   Krug, Edward C ^a,b   Nash, Paul B ^a,c   Curiel, Tyler J ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Denver Public Schools   (United States)

^c HESKA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ARTEMISIN; DIHYDROARTEMISININ; DIMETHYL SULFOXIDE; MESYLIC ACID ETHYL ESTER; METHYLNITRONITROSOGUANIDINE; PYRIMETHAMINE; SERUM ALBUMIN; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; FEMALE; MOUSE; MUTANT; NONHUMAN; PARASITE CULTIVATION; PARASITE ISOLATION; PARASITE VIRULENCE; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 0031968595     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517411     Document Type: Article

References (15)

1. Ke OY, Krug EC, Marr JJ, Berens RL. Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimicrob Agents Chemother 1990;34:1961-5.
2. Holfels E, McAuley J, Mack D, Milhous WK, McLeod R. In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii. Antimicrob Agents Chemother 1994;38:1392-6.
3. China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials. Chemical studies on qinghaosu (artemisinin). J Tradit Chin Med 1982;2:3-8.
4. China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials. Clinical studies on the treatment of malaria with qinghaosu and its derivatives. J Tradit Chin Med 1982;2:45-50.
5. Karbwang J, Na-Bangchang K, Thanavibul A, Ditta-in M, Harinasuta T. A comparative clinical trial of two different regimens of artemether plus mefloquine in multidrug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1995;89:296-8.
6. Meshnick SR. The mode of action of antimalarial endoperoxides. Trans R Soc Trop Med Hyg 1994;88(suppl):S31-2.
7. Pfefferkorn ER, Pfefferkorn LC. Arabinosyl nucleosides inhibit Toxoplasma gondii and allow the selection of resistant mutants. J Parasitol 1976;62:993-9.
8. Pfefferkorn ER, Pfefferkorn LC. Toxoplasma gondii: characterization of a mutant resistant to 5-luorodeoxyuridine. Exp Parasitol 1977;42:44-55.
9. Krug EC, Marr JJ, Berens RL. Purine metabolism in Toxoplasma gondii. J Biol Chem 1989;264:10,601-7.
10. Daggett PM, Nerad TA. Cryopreservation of Toxoplasma gondii. In: Lee JJ, Soldo AT, eds. Protocols in protozoology. Lawrence, KS: Society of Protozoology, 1992:A-85.
11. Derouin F, Chastang C. Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture. Antimicrob Agents Chemother 1988;32:303-7.
12. Baum KF, Berens RL, Jones RH, Marr JJ. A new method for cloning Giardia lamblia, with a discussion of the statistical considerations of limiting dilution. J Parasitol 1988;74:267-9.
13. Luft BJ. Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis. J Infect Dis 1986;154:692-4.
14. Brossi A, Venugopalan B, Dominguez Gerpe L, Yeh HJ, et al. Arteether, a new antimalarial drug: synthesis and antimalarial properties. J Med Chem 1988;31:645-50.
15. Martiney JA, Cerami A, Slater AF. Verapamil reversal of chloroquine resistance in the malaria parasite Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect. J Biol Chem 1995;270:22, 393-8.